Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery
Menée à partir de données portant sur 1 924 patients atteints d'un pseudomyxome péritonéal traité par chirurgie cytoréductive entre 1993 et 2017, cette étude compare l'efficacité, du point de vue de la survie globale, de la chirurgie cytoréductive seule par rapport à une chirurgie cytoréductive suivie d'une chimiothérapie intrapéritonéale hyperthermique
In this issue of JAMA Surgery, Kusamura et al demonstrate outcomes of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) among patients with pseudomyxoma peritonei (PMP). This work used the Peritoneal Surface Oncology Group International (PSOGI) registry of approximately 3500 patients treated during 24 years in more than 20 centers worldwide. This report seeks to provide the science to what most of us who care for patients with appendiceal tumors believe, that HIPEC helps more than it hurts. With the power of statistics, the authors have achieved this, to a point. Those of us who believe in HIPEC will find the validation we seek. However, we should be cautious if we are to be truly scientific.
JAMA Surgery , éditorial, 2020